Eyenovia
EYEN

$0.5083

1.56%

Market Cap: $39.1M

About: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Employees: 57

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

400% more call options, than puts

Call options by funds: $30K | Put options by funds: $6K

24% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 17

7% more funds holding

Funds holding: 55 [Q1] → 59 (+4) [Q2]

4.76% more ownership

Funds ownership: 16.99% [Q1] → 21.75% (+4.76%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

12% less capital invested

Capital invested by funds: $7.94M [Q1] → $6.96M (-$979K) [Q2]

45% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 20

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$12

2,261%

upside

Avg. target

$12

2,261%

upside

High target

$12

2,261%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Matthew Caufield 26% 1-year accuracy 10 / 38 met price target	2,261%upside $12	Buy Reiterated	13 Aug 2024
HC Wainwright & Co. Matthew Caufield 26% 1-year accuracy 10 / 38 met price target	2,261%upside $12	Buy Reiterated	24 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about EYEN published over the past 30 days

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

TAIPEI , Sept. 9, 2024 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United States of its new ophthalmic drug, Clobetasol Propionate Ophthalmic Suspension, 0.05% (APP13007), manufactured by Bora Pharmaceuticals Ophthalmic (hereinafter referred to as "Bora," 6472.TW).

Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024 Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024

Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition

Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer

Eyenovia Announces Closing of Public Offering

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today the closing of its public offering of 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").

Eyenovia Announces Closing of Public Offering

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.

Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?

Eyenovia Announces Pricing of $5.14 Million Public Offering

NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40 (the "Offering").

Eyenovia Announces Pricing of $5.14 Million Public Offering

Eyenovia, Inc. Announces Proposed Public Offering

NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it intends to offer and sell shares of its common stock (or pre-funded warrants in lieu thereof) in a best efforts offering. All of the securities to be sold in the offering are to be offered by Eyenovia. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering (the "Offering").

Eyenovia, Inc. Announces Proposed Public Offering

Zacks Investment Research

Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know

Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer Bren Kern - Chief Operating Officer John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Kemp Dolliver - Brookline Capital Markets Lachlan Hanbury-Brown - William Blair Matthew Caufield - H.C. Wainwright Operator Greetings.

Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.

Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates

See News Rankings